Idelalisib with Maraviroc Interaction Details
Brand Names Associated with Idelalisib
- Idelalisib
- Zydelig®
Brand Names Associated with Maraviroc
- Maraviroc
- Selzentry®
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Jan 04, 2024
Interaction Effect
Increased exposure of maraviroc
Interaction Summary
Concomitant use of maraviroc (a CYP3A substrate) with a strong CYP3A inhibitor may result in increased exposure of maraviroc, which has been demonstrated with specific agents during pharmacokinetic studies. The concomitant use of maraviroc with a potent CYP3A inhibitor is contraindicated in adult and pediatric patients with CrCl less than 30 mL/min and in those with ESRD on regular hemodialysis. In adults with CrCl 30 mL/min or greater taking a concurrent strong CYP3A inhibitor (with or without a strong CYP3A inducer), reduce the maraviroc dose to 150 mg orally twice daily. In pediatric patients with CrCl 30 mL/min or greater, reduce the dose as follows: 50 mg twice daily for those 10 to less than 20 kg, 75 mg (if taking the tablet) or 80 mg (if taking oral solution) twice daily for those 20 to less than 30 kg), 100 mg twice daily for those 30 to less than 40 kg, and 150 mg twice daily for those 40 kg or greater.
Severity
Contraindicated
Onset
Unspecified
Evidence
Established
How To Manage Interaction
The concomitant use of maraviroc (a CYP3A substrate) with a potent CYP3A inhibitor is contraindicated in adult and pediatric patients with CrCl less than 30 mL/min and in those with ESRD on regular hemodialysis. In adults with CrCl 30 mL/min or greater taking a concurrent strong CYP3A inhibitor (with or without a strong CYP3A inducer), reduce the maraviroc dose to 150 mg orally twice daily. In pediatric patients with CrCl 30 mL/min or greater, reduce the dose as follows: 50 mg twice daily for those 10 to less than 20 kg, 75 mg (if taking the tablet) or 80 mg (if taking oral solution) twice daily for those 20 to less than 30 kg), 100 mg twice daily for those 30 to less than 40 kg, and 150 mg twice daily for those 40 kg or greater.
Mechanism Of Interaction
Inhibition of CYP3A-mediated metabolism of maraviroc
Literature Reports
A) Concomitant administration of ketoconazole (a strong CYP3A inhibitor) and maraviroc resulted in increased maraviroc AUC and plasma concentrations. When ketoconazole 400 mg once daily was administered concurrently with maraviroc 100 mg twice daily in 12 patients, the ratio of maraviroc pharmacokinetic parameters with ketoconazole to without ketoconazole was: Cmin 3.75 (90% CI, 3.01 to 4.69), AUC 5 (90% CI, 3.98 to 6.29), and Cmax 3.38 (90% CI, 2.38 to 4.78) .
B) Concomitant administration of lopinavir/ritonavir (a strong CYP3A inhibitor) and maraviroc resulted in increased maraviroc AUC and plasma concentrations. When lopinavir 400 mg/ritonavir 100 mg twice daily was administered concurrently with maraviroc 300 mg twice daily in 11 patients, the ratio of maraviroc pharmacokinetic parameters with lopinavir/ritonavir to without lopinavir/ritonavir was: Cmin 9.24 (90% CI, 7.98 to 10.7), AUC 3.95 (90% CI, 3.43 to 4.56), and Cmax 1.97 (90% CI, 1.66 to 2.34) .
C) Concomitant administration of maraviroc and lopinavir/ritonavir (a strong CYP3A inhibitor) plus efavirenz resulted in increased maraviroc AUC and plasma concentrations. When maraviroc 300 mg twice daily was administered concurrently with lopinavir 400 mg/ritonavir 100 mg twice daily plus efavirenz 600 mg once daily in 11 patients, the ratio of maraviroc pharmacokinetic parameters with lopinavir/ritonavir plus efavirenz to without lopinavir/ritonavir plus efavirenz was: Cmin 6.29 (90% CI, 4.72-8.39), AUC 2.53 (90% CI, 2.24-2.87), and Cmax 1.25 (90% CI, 1.01 to 1.55) .
D) Concomitant administration of maraviroc and ritonavir (a strong CYP3A inhibitor) resulted in increased maraviroc AUC and plasma concentrations. When ritonavir 100 mg twice daily was administered concurrently with maraviroc 100 mg twice daily in 8 patients, the ratio of maraviroc pharmacokinetic parameters with ritonavir to without ritonavir was: Cmin 4.55 (90% CI, 3.37 to 6.13), AUC 2.61 (90% CI, 1.92 to 3.56), and Cmax 1.28 (90% CI, 0.79 to 2.09) .
E) Concomitant administration of maraviroc and saquinavir/ritonavir (a strong CYP3A inhibitor) resulted in increased maraviroc AUC and plasma concentrations. When saquinavir 1000 mg/ritonavir 100 mg twice daily was administered concurrently with maraviroc 100 mg twice daily in 11 patients, the ratio of maraviroc pharmacokinetic parameters with saquinavir/ritonavir to without saquinavir/ritonavir was: Cmin 11.3 (90% CI, 8.96 to 14.1), AUC 9.77 (90% CI, 7.87 to 12.14), and Cmax 4.78 (90% CI, 3.41 to 6.71) .
F) Concomitant administration of maraviroc and saquinavir/ritonavir (a strong CYP3A inhibitor) plus efavirenz resulted in increased maraviroc AUC and plasma concentrations. When maraviroc 100 mg twice daily was administered concurrently with saquinavir 1000 mg/ritonavir 100 mg twice daily plus efavirenz 600 mg once daily in 11 patients, the ratio of maraviroc pharmacokinetic parameters with saquinavir/ritonavir plus efavirenz to without saquinavir/ritonavir plus efavirenz was: Cmin 8.42 (90% CI, 6.46 to 10.97), AUC 5 (90% CI, 4.26 to 5.87), and Cmax 2.26 (90% CI, 1.64 to 3.11) .
G) When maraviroc 150 mg twice daily was administered concurrently with boceprevir 800 mg three times/day (N=14), maraviroc AUC was increased 3-fold and Cmax was increased 3.33-fold .
H) When maraviroc 150 mg twice daily was administered concurrently with elvitegravir 150 mg/ritonavir 100 mg once daily (N=11), maraviroc AUC was increased 2.86-fold and Cmax was increased 2.15-fold .
Idelalisib Overview
-
Idelalisib is used along with another medication rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) in people whose cancer came back after receiving other cancer treatments. It is also used to treat certain types of follicular lymphoma (FL; a type of cancer that begins in the white blood cells) and small lymphocytic lymphoma (SLL:a type of cancer that begins in the white blood cells) in people whose cancer came back after being treated with at least 2 other cancer treatments. Idelalisib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
Maraviroc Overview
-
Maraviroc is used along with other medications to treat a certain type of human immunodeficiency virus (HIV) infection in adults and children who weigh at least 4.4 lb (2 kg). Maraviroc is in a class of medications called HIV entry and fusion inhibitors. It works by decreasing the amount of HIV in the blood. Although maraviroc does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Return To Our Drug Interaction Homepage
Feedback, Question Or Comment About This Information?
Ask Dr. Brian Staiger, PharmD, our medical editor, directly! He's always more than happy to assist.
Definitions
Severity Categories
Contraindicated
These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.
Major
This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.
Moderate
This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.
Minor
While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.
Onset
Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.
Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.
Evidence
Level of documentation of the interaction.
Established: The interaction is documented and substantiated in peer-reviewed medical literature.
Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.
How To Manage The Interaction
Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.
It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.
Mechanism Of Interaction
The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.
Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.
Where Does Our Information Come From?
Information for our drug interactions is compiled from several drug compendia, including:
The prescribing information for each drug, as published on DailyMED, is also used.
Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.
The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.